Anti-ACTRII antibody-GLP1(Qilu Pharmaceuticals)

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameAnti-ACTRII antibody-GLP1(Qilu Pharmaceuticals)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionActivin receptor type-2 antagonistsGlucagon-like peptide 1 receptor agonists
TargetsActivin receptor type-2Glucagon-like peptide 1 receptor
Therapy Area/IndicationsObesityHeart FailurePulmonary Arterial Hypertension +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Qilu Pharmaceutical R&D Center Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Qilu Pharmaceutical R&D Center Co Ltd
Inactive CompaniesN/A
Active IndicationsObesityHeart FailurePulmonary Arterial Hypertension +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A